57 results
424B5
TPST
Tempest Therapeutics Inc
20 Jun 24
Prospectus supplement for primary offering
8:32am
are amezalpat and TPST-1495, which we believe are the first clinical-stage molecules designed to inhibit their respective targets. Amezalpat is a selective … to treat their respective targets; and a third program in preclinical studies that could be the first to target TREX-1, a key cellular enzyme that regulates
8-K
EX-10.1
us2cf9867ex
21 Jun 22
Departure of Directors or Certain Officers
7:31am
PRE 14A
7268u0woah
22 Apr 22
Preliminary proxy
4:01pm
424B5
87t ycau81b
23 Jul 21
Prospectus supplement for primary offering
4:38pm